The Tohoku Journal of Experimental Medicine · 2016 · 18 citations · 33 references
Veterinary MedicineChild HealthInfectious DiseasesMolecular VirologyPediatric Infectious DiseasesVirologyAntiviral TherapyRespiratory Disease Epidemiology In ChildrenRespiratory Infectious DiseasesViral DiagnosticsViral EpidemiologyViral InfectionsFever DetectionInfluenza Antiviral TherapyInfluenza TreatmentLong-term Viral SheddingPediatric Influenza EpidemiologyPediatric SurveillanceViral Shedding AssessmentVirus Diseases
The current School Health and Safety Act in Japan states that children with influenza infection should stay home until day 6(th) after symptoms onset. This was an amendment of a previous version recommending school return on day 3 after defervescence. Here, we investigated the duration of fever and virus shedding after laninamivir treatment in 7 children infected with influenza A(H3N2) virus and 21 children with influenza B virus in relation to the school return timing recommended by the School Health and Safety Act during the 2011-2012 influenza season. Nasal discharge was collected on the first, second, and third hospital visits and virus titers were assessed by virus culture and real-time PCR. Duration of fever after laninamivir treatment was 1 day longer for influenza B than for influenza A(H3N2). Virus detection rates with 50% tissue culture infectious dose and viral RNA were highest at the first visit and gradually decreased at subsequent visits. Virus positivity rates were detectable at the time of defervescence in less than half of the enrolled patients (14.3-42.9%). Virus shedding rates were similarly low (0.0-19.0%) on day 3 or later from defervescence and on day 6 or later from fever onset (school return dates per the old and current School Health and Safety Act) regardless of the influenza type. In conclusion, despite the higher efficacy of laninamivir against A(H3N2) viruses than B viruses, viral shedding is low after return to school for both types, regardless of the version of the School Health and Safety Act.
33
Universal primer set for the full-length amplification of all influenza A viruses
E. Hoffmann, Jürgen Stech, Yi Guan et al. · Archives of Virology · 2001 · 2.1K citations · Full text
Arnold S. Monto, Jennifer L. McKimm‐Breschkin, Catherine A. Macken et al. · Antimicrobial Agents and Chemotherapy · 2006 · 364 citations · Full text
Akira Watanabe, Shan‐Chwen Chang, Min Ja Kim et al. · Clinical Infectious Diseases · 2010 · 208 citations
Naoki Kawai, Hideyuki Ikematsu, Norio Iwaki et al. · Clinical Infectious Diseases · 2006 · 192 citations